Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEENAKSHI C PATEL

Allopathic & Osteopathic Physicians Internal Medicine Geriatric Medicine

NPI
1568458362
CMS profile
298127
Location
CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$99,298.59

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEENAKSHI C PATEL

NPI 1568458362 · CMS profile ID 298127

Allopathic & Osteopathic Physicians / Internal Medicine / Geriatric Medicine

CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568458362?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEENAKSHI C PATEL, NPI 1568458362, CMS profile ID 298127. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568458362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MEENAKSHI C PATEL, NPI 1568458362, CMS profile ID 298127. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568458362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MEENAKSHI C PATEL, NPI 1568458362, CMS profile ID 298127, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1568458362?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $99,298.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.8807/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833402189 CMS
Lilly USA, LLC $1,000.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669259 CMS
Novartis Pharmaceuticals Corporation $24.3507/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813149253 CMS
AbbVie Inc. $8.2607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795542671 CMS
Janssen Pharmaceuticals, Inc $6.9207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788392127 CMS
Janssen Pharmaceuticals, Inc $2.8707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788392129 CMS
AstraZeneca Pharmaceuticals LP $2,350.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829303337 CMS
AstraZeneca Pharmaceuticals LP $13.0306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829456077 CMS
AbbVie Inc. $12.5806/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795542665 CMS
Sunovion Pharmaceuticals Inc. $13.7706/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821843787 CMS
Amgen Inc. $12.8206/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605397 CMS
Janssen Pharmaceuticals, Inc $750.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788392109 CMS
Lilly USA, LLC $16.2506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818587751 CMS
Lilly USA, LLC $0.4506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818650521 CMS
PFIZER INC. $11.3306/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833537275 CMS
AstraZeneca Pharmaceuticals LP $45.4406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829952419 CMS
AstraZeneca Pharmaceuticals LP $441.0006/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829737253 CMS
AstraZeneca Pharmaceuticals LP $14.5306/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829926205 CMS
AstraZeneca Pharmaceuticals LP $86.4006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830036367 CMS
Janssen Pharmaceuticals, Inc $750.0006/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788392107 CMS
Novartis Pharmaceuticals Corporation $15.9206/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813149249 CMS
Amgen Inc. $14.4006/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605409 CMS
Lilly USA, LLC $1,000.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818611061 CMS
Lilly USA, LLC $1,000.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669257 CMS
PFIZER INC. $14.8005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833491447 CMS
AbbVie Inc. $18.2405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795542659 CMS
Avanir Pharmaceuticals, Inc. $4,830.0005/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801027487 CMS
AbbVie Inc. $16.5805/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795542653 CMS
AstraZeneca Pharmaceuticals LP $1,200.0005/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829916079 CMS
Biohaven Pharmaceuticals, Inc. $20.7305/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852587407 CMS
Amarin Pharma Inc. $15.5205/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815311301 CMS
Amgen Inc. $10.0705/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826391021 CMS
PFIZER INC. $20.7505/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833519287 CMS
Astellas Pharma US Inc $12.2705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821486261 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4604/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763709348 CMS
Lilly USA, LLC $1,000.0004/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818650517 CMS
Lilly USA, LLC $1,000.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669255 CMS
AstraZeneca Pharmaceuticals LP $70.2204/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829458409 CMS
Amgen Inc. $13.1704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826391027 CMS
AbbVie Inc. $21.7504/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795542647 CMS
AstraZeneca Pharmaceuticals LP $250.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829621187 CMS
Novo Nordisk Inc $12.6604/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810902149 CMS
Lilly USA, LLC $1,000.0004/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818587743 CMS
Lilly USA, LLC $1,000.0004/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643239 CMS
AstraZeneca Pharmaceuticals LP $1,800.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829456315 CMS
Lilly USA, LLC $1,000.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818641479 CMS
SANOFI-AVENTIS U.S. LLC $13.7904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843420231 CMS
Lilly USA, LLC $1,000.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818587741 CMS
Lilly USA, LLC $9.9504/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643235 CMS
Lilly USA, LLC $0.4304/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818643237 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $155,849.56 408
PY2020 $82,569.84 156
PY2021 $99,298.59 194
PY2022 $88,314.59 168
PY2023 $112,736.88 247
PY2024 $61,616.16 212
PY2025 $43,797.77 124

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,537.82 7
PY2025 Principal investigator $444,631.11 28
PY2024 Principal investigator $612,325.61 17
PY2023 Recipient $1,994.34 1
PY2023 Principal investigator $713,040.13 21
PY2022 Recipient $1,326.00 2
PY2022 Principal investigator $746,748.87 79
PY2021 Recipient $72,107.04 3
PY2021 Principal investigator $318,020.59 80
PY2020 Principal investigator $127,496.99 59
PY2019 Recipient $16,297.00 4
PY2019 Principal investigator $286,486.58 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $23,328.00 12/29/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335846
Principal investigator 1 Janssen Research & Development, LLC $11,134.00 12/22/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335831
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/12/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335768
Principal investigator 1 Janssen Research & Development, LLC $270.00 12/12/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335874
Principal investigator 1 Janssen Research & Development, LLC $2,232.00 12/01/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335792
Principal investigator 1 Janssen Research & Development, LLC $39,580.00 11/13/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335776
Principal investigator 1 Janssen Research & Development, LLC $19,330.00 11/03/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335898
Principal investigator 1 Janssen Research & Development, LLC $9,220.00 08/11/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335882
Principal investigator 1 Janssen Research & Development, LLC $900.00 08/08/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335822
Principal investigator 1 Janssen Research & Development, LLC $60.00 07/14/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335751
Principal investigator 1 Janssen Research & Development, LLC $2,687.00 07/11/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335867
Principal investigator 1 Janssen Research & Development, LLC $3,141.00 06/09/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335800
Principal investigator 1 Janssen Research & Development, LLC $74.99 06/09/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335816
Principal investigator 1 Eli Lilly and Company $184.58 05/27/2025 Non-covered Recipient Entity
LCGK RSRCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887220
Principal investigator 1 Janssen Research & Development, LLC $35,622.00 05/08/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335889
Principal investigator 1 Janssen Research & Development, LLC $27,706.00 03/24/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335905
Principal investigator 1 ACADIA Pharmaceuticals Inc $300.00 03/14/2025 Non-covered Recipient Entity
M PATEL
ACP-204-006 No dispute reported 06/30/2026 1245933903
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,198.00 03/14/2025 Non-covered Recipient Entity
M PATEL
ACP-204-006 No dispute reported 06/30/2026 1245933905
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,000.00 03/14/2025 Non-covered Recipient Entity
M PATEL
ACP-204-006 No dispute reported 06/30/2026 1245933907
Principal investigator 1 Janssen Research & Development, LLC $53,070.00 02/24/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335854
Principal investigator 1 Janssen Research & Development, LLC $6,930.00 02/24/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335862
Principal investigator 1 Eli Lilly and Company $46,575.00 02/18/2025 Non-covered Recipient Entity
VALLEY MEDICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187893140
Principal investigator 1 Eli Lilly and Company $231.54 02/04/2025 Non-covered Recipient Entity
VALLEY MEDICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890998
Principal investigator 1 Janssen Research & Development, LLC $8,970.00 02/03/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335811
Principal investigator 1 Janssen Research & Development, LLC $7,350.00 01/27/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335759
Principal investigator 1 Janssen Research & Development, LLC $3,110.00 01/27/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335784
Principal investigator 1 Janssen Research & Development, LLC $72,529.00 01/27/2025 Non-covered Recipient Entity
M PATEL
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175335838
Recipient ACADIA Pharmaceuticals Inc $319.51 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932663
Recipient ACADIA Pharmaceuticals Inc $461.95 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932665
Recipient ACADIA Pharmaceuticals Inc $230.25 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932667
Recipient ACADIA Pharmaceuticals Inc $96.81 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932669
Recipient ACADIA Pharmaceuticals Inc $125.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932671
Recipient ACADIA Pharmaceuticals Inc $170.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932673
Recipient ACADIA Pharmaceuticals Inc $134.30 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932675
Principal investigator 1 Eli Lilly and Company $58,398.00 01/07/2025 Non-covered Recipient Entity
VALLEY MEDICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890996